Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArriVent BioPharmaAVBP -4.98%12 Cash Ratio is 13.06 as of Mar. 2026, which is 5% below its 10-year median of 13.76. GuruFocus rates AVBP with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,381 Biotechnology companies, ArriVent BioPharma ranks better than 85.95% on this metric.
ArriVent BioPharma has a Cash Ratio of 13.06. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for ArriVent BioPharma's Cash Ratio or its related term are showing as below:
AVBP'
s Cash Ratio Range Over the Past 10 Years
Min: 12 Med: 13.76 Max: 31.81
Current: 13.06
During the past 5 years, ArriVent BioPharma's highest Cash Ratio was 31.81. The lowest was 12.00. And the median was 13.76.
AVBP's Cash Ratio is ranked better than 85.95% of 1381
companies
in the Biotechnology industry
Industry Median: 2.95
vs AVBP: 13.06
ArriVent BioPharma (NAS:AVBP) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
ArriVent BioPharma Cash Ratio Related Terms
ArriVent BioPharma Cash Ratio Historical Data
* Premium members only.
The historical data trend for ArriVent BioPharma's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ArriVent BioPharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ArriVent BioPharma Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's Cash Ratio distribution charts can be found below:
* The bar in red indicates where ArriVent BioPharma's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ArriVent BioPharma (AVBP) has a Cash Ratio of 13.06 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ArriVent BioPharma and its competitors. This is near median its historical median of 13.76. Over the past decade, ArriVent BioPharma's Cash Ratio has ranged from 12.00 to 31.81. According to the industry distribution chart, ArriVent BioPharma ranks #194 out of 1381 companies in the Biotechnology industry, placing it in the top 14%.
Is ArriVent BioPharma's Cash Ratio too high?
ArriVent BioPharma's current Cash Ratio of 13.06 is near median its 10-year median of 13.76. Over the past 10 years, this metric has ranged from a low of 12.00 to a high of 31.81. The Biotechnology industry median Cash Ratio is 2.95. ArriVent BioPharma's value of 13.06 is 342.7% above this industry median. Based on the distribution chart, ArriVent BioPharma ranks #194 out of 1381 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ArriVent BioPharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does ArriVent BioPharma's Cash Ratio compare to VIR and SEPN?
According to the Biotechnology industry distribution chart, ArriVent BioPharma ranks #194 out of 1381 companies for Cash Ratio. This places ArriVent BioPharma in the top 14% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.95. ArriVent BioPharma's value of 13.06 is 342.7% above this benchmark. Historically, ArriVent BioPharma's own Cash Ratio has ranged from 12.00 to 31.81 over the past decade. While the company's 10-year median is 13.76 vs. the industry median of 2.95, ArriVent BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,381 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ArriVent BioPharma's current Cash Ratio of 13.06 is 342.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ArriVent BioPharma and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ArriVent BioPharma's current Cash Ratio is 13.06, which is near median its own 10-year median of 13.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArriVent BioPharma stock overvalued right now?
ArriVent BioPharma (AVBP) has a current Cash Ratio of 13.06. The current Cash Ratio is 13.06, which is near median its 10-year median of 13.76 and 342.7% above the Biotechnology industry median of 2.95. ArriVent BioPharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For ArriVent BioPharma (AVBP), the current Cash Ratio is 13.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
12GF Score
Get the complete analysis for AVBP
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVBP has been successfully added to your 
